MAI Capital Management
VOR icon

MAI Capital Management’s Vor Biopharma VOR Stock Holding History

MAI Capital Management’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40
Closed -$714 – 4645
2026
Q1 		$714 Hold
40
– – ﹤0.01% 4296
2025
Q4 		$524 Hold
40
– – ﹤0.01% 3815
2025
Q3 		$1.95K Sell
40
-143
-78% -$5.75K ﹤0.01% 3317
2025
Q2 		$5.92K Sell
183
-14,235
-99% -$126K ﹤0.01% 2979
2025
Q1 		$207K Buy
14,418
+258
+2% +$6.2K ﹤0.01% 1105
2024
Q4 		$314K Sell
14,160
-9,635
-40% -$160K ﹤0.01% 978
2024
Q3 		$333K Buy
23,795
+292
+1% +$5.32K ﹤0.01% 843
2024
Q2 		$470K Buy
23,503
+5,210
+28% +$169K ﹤0.01% 833
2024
Q1 		$867K Buy
18,293
+435
+2% +$19.1K 0.01% 627
2023
Q4 		$804K Buy
+17,858
New +$737K 0.01% 541

Other funds holding VOR

TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
FCPM III Services
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VR Adviser
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Caligan Partners
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

MAI Capital Management's VOR Position: Q2 2026 in Review

MAI Capital Management sold out of Vor Biopharma (VOR) in Q2 2026, closing a stake of 40 shares — an estimated $714 sold.

MAI Capital Management first reported a position in VOR in Q4 2023 and held it in 10 quarters. The position peaked at $867K in Q1 2024. 102 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • MAI Capital Management reported no remaining Vor Biopharma position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 40 Vor Biopharma shares in Q2 2026, an estimated $714.
  • MAI Capital Management first reported a position in Vor Biopharma in Q4 2023 and held it in 10 quarters.
  • MAI Capital Management's Vor Biopharma position peaked at $867K in Q1 2024.
  • 102 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.